<?xml version='1.0' encoding='utf-8'?>
<document id="9724561"><sentence text="Stereoselective pharmacokinetics of chlorpheniramine and the effect of ranitidine."><entity charOffset="36-52" id="DDI-PubMed.9724561.s1.e0" text="chlorpheniramine" /><entity charOffset="71-81" id="DDI-PubMed.9724561.s1.e1" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.9724561.s1.e0" e2="DDI-PubMed.9724561.s1.e0" /><pair ddi="false" e1="DDI-PubMed.9724561.s1.e0" e2="DDI-PubMed.9724561.s1.e1" /></sentence><sentence text="This single-dose, randomized, crossover study was carried out to investigate the potential effect of ranitidine on the pharmacokinetics of chlorpheniramine"><entity charOffset="101-111" id="DDI-PubMed.9724561.s2.e0" text="ranitidine" /><entity charOffset="139-155" id="DDI-PubMed.9724561.s2.e1" text="chlorpheniramine" /><pair ddi="false" e1="DDI-PubMed.9724561.s2.e0" e2="DDI-PubMed.9724561.s2.e0" /><pair ddi="false" e1="DDI-PubMed.9724561.s2.e0" e2="DDI-PubMed.9724561.s2.e1" /></sentence><sentence text=" The study also afforded an opportunity to add to the limited data currently available on the stereoselective pharmacokinetics of chlorpheniramine"><entity charOffset="130-146" id="DDI-PubMed.9724561.s3.e0" text="chlorpheniramine" /></sentence><sentence text=" Healthy subjects received a single oral 4 mg dose of racemic chlorpheniramine on two separate occasions: alone, and on day 6 of dosing with ranitidine 75 mg b"><entity charOffset="54-78" id="DDI-PubMed.9724561.s4.e0" text="racemic chlorpheniramine" /><entity charOffset="141-151" id="DDI-PubMed.9724561.s4.e1" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.9724561.s4.e0" e2="DDI-PubMed.9724561.s4.e0" /><pair ddi="false" e1="DDI-PubMed.9724561.s4.e0" e2="DDI-PubMed.9724561.s4.e1" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=" for 8 days" /><sentence text=" Serum concentrations and urinary recovery of (S)-(+)- and (R)-(-)-chlorpheniramine were unaffected by administration of ranitidine, indicating no pharmacokinetic drug-drug interaction"><entity charOffset="46-83" id="DDI-PubMed.9724561.s8.e0" text="(S)-(+)- and (R)-(-)-chlorpheniramine" /><entity charOffset="121-131" id="DDI-PubMed.9724561.s8.e1" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.9724561.s8.e0" e2="DDI-PubMed.9724561.s8.e0" /><pair ddi="false" e1="DDI-PubMed.9724561.s8.e0" e2="DDI-PubMed.9724561.s8.e1" /></sentence><sentence text=" The observed chlorpheniramine pharmacokinetic data were consistent with previous data and indicated approximately 2"><entity charOffset="14-30" id="DDI-PubMed.9724561.s9.e0" text="chlorpheniramine" /></sentence><sentence text="5-fold higher serum concentrations of the (S)-(+) enantiomer" /><sentence text=" Previously reported high variability in chlorpheniramine pharmacokinetics was greatly reduced by well-controlled food and fluid intake"><entity charOffset="41-57" id="DDI-PubMed.9724561.s11.e0" text="chlorpheniramine" /></sentence><sentence text="" /></document>